SEC Form 4 · accession 0001209191-18-014826
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard King
Officer — Chief Operating Officer
Period of report
Feb 28, 2018
Accepted (ET)
Mar 1, 2018 · 12:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 28, 2018 | A | 10,000 | $25.07 | A | 39,661 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were purchased at prices ranging from $25.05 to $25.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2Includes 1,536 shares purchased on 11/30/17 through the issuer's employee stock purchase plan.